FGF23 in chronic kidney disease

Advances in Experimental Medicine and Biology

Volumn 728, Issue , 2012, Pages 107-125

  Wahl, Patricia ^a   Wolf, Myles ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BICARBONATE; CALCIUM ACETATE; CALCIUM BICARBONATE; FIBROBLAST GROWTH FACTOR 23; PARATHYROID HORMONE; PHOSPHATE; SEVELAMER; UNCLASSIFIED DRUG; VITAMIN D; FIBROBLAST GROWTH FACTOR; MINERAL;

ADVERSE OUTCOME; ARTICLE; CHRONIC KIDNEY DISEASE; DIALYSIS; DISEASE CLASSIFICATION; DISORDERS OF MINERAL, ELECTROLYTE AND METAL METABOLISM; HEMATOLOGIC DISEASE; HIGH RISK PATIENT; HORMONE RELEASE; HUMAN; KIDNEY DYSFUNCTION; KIDNEY FUNCTION; METABOLIC DISORDER; MINERAL METABOLISM; MINERAL METABOLISM DISORDER; MORTALITY; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; RISK ASSESSMENT; SCREENING; SECONDARY HYPERPARATHYROIDISM; ANIMAL; CHRONIC DISEASE; KIDNEY DISEASE; METABOLISM; REVIEW;

ANIMALS; CHRONIC DISEASE; FIBROBLAST GROWTH FACTORS; HUMANS; KIDNEY DISEASES; MINERALS;

EID: 84859536160     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4614-0887-1_8     Document Type: Article

References (108)

1. Coresh J, Selvin E, Stevens LA et al. Prevalence of chronic kidney disease in the United States. JAMA 2007; 298:2038-2047
2. Snyder JJ, Foley RN, Collins AJ. Prevalence of CKD in the United States: a sensitivity analysis using the National Health andNutritionExamination Survey (NHANES) 1999-2004. AmJKidney Dis 2009; 53:218-228
3. USRDS: the United States Renal Data System. Am J Kidney Dis 2003; 42:1-230
4. U S Renal Data System, USRDS 2010 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2010
5. Muntner P, He J, Hamm L et al. Renal insufficiency and subsequent death resulting from cardiovascular disease in the United States. J Am Soc Nephrol 2002; 13:745-753
6. Levin A. Clinical epidemiology of cardiovascular disease in chronic kidney disease prior to dialysis. Semin Dial 2003; 16:101-105
7. SchiffrinEL, LipmanML, Mann JF. Chronic kidney disease: effects on the cardiovascular system. Circulation 2007; 116:85-97
8. Weiner DE, Tighiouart H, Stark PC et al. Kidney disease as a risk factor for recurrent cardiovascular disease and mortality. Am J Kidney Dis 2004; 44:198-206
9. Elsayed EF, Tighiouart H, Griffith J et al. Cardiovascular disease and subsequent kidney disease. Arch Intern Med 2007; 167:1130-1136
10. Go AS, Chertow GM, Fan D et al. Chronic kidney disease and the risks of death, cardiovascular events and hospitalization. N Engl J Med 2004; 351:1296-1305
11. Keith DS, Nichols GA, Gullion CM et al. Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization. Arch Intern Med 2004; 164:659-663
12. Yu HT. Progression of chronic renal failure. Arch Intern Med 2003; 163:1417-1429
13. Brenner BM. Remission of renal disease: recounting the challenge, acquiring the goal. J Clin Invest 2002; 110:1753-1758
14. Schieppati A, Remuzzi G. The June 2003 Barry M. Brenner Comgan lecture. The future of renoprotection: frustration and promises. Kidney Int 2003; 64:1947-1955
15. K/DOQI clinical practice guidelines for evaluation of chronic kidney disease: evaluation, classification and stratification. Am J Kidney Dis 2002; 39:S46-S76
16. Stevens LA, Coresh J, Greene T et al. Assessing kidney function-measured and estimated glomerular filtration rate. N Engl J Med 2006; 354:2473-2483
17. Stevens LA, Levey AS. Measured GFR as a confirmatory test for estimated GFR. J Am Soc Nephrol 2009; 20:2305-2313
18. Perrone RD, Madias NE, Levey AS. Serum creatinine as an index of renal function: new insights into old concepts. Clin Chem 1992; 38:1933-1953
19. Abboud H, Henrich WL. Stage IV chronic kidney disease. N Engl J Med 2009;362:56-65
20. Block GA, Klassen PS, Lazarus JM et al. Mineral metabolism, mortality and morbidity in maintenance hemodialysis. J Am Soc Nephrol 2004; 15:2208-2218
21. Kestenbaum B, Sampson JN, Rudser KD et al. Serum phosphate levels and mortality risk among people with chronic kidney disease. J Am Soc Nephrol 2005; 16:520-528
22. Bhuriya R, Li S, Chen SC et al. Plasma parathyroid hormone level and prevalent cardiovascular disease in CKD stages3and4: an analysis from the Kidney Early Evaluation Program (KEEP). Am JKidneyDis2009;53:S3-10
23. Voormolen N, Noordzij M, Grootendorst DC et al. High plasma phosphate as a risk factor for decline in renal function and mortality in predialysis patients. Nephrol Dial Transplant 2007; 22:2909-2916
24. Kovesdy CP, Ahmadzadeh S, Anderson JE et al. Secondary hyperparathyroidism is associated with higher mortality in men with moderate to severe chronic kidney disease. Kidney Int 2008; 73:1296-1302
25. Slatopolsky E. The role of calcium, phosphorus and vitamin D metabolism in the development of secondary hyperparathyroidism. Nephrol Dial Transplant 1998; 13 Suppl 3:3-8
26. Juppner H, Potts JT Jr. Immunoassays for the detection of parathyroid hormone. J Bone Miner Res 2002; 17 Suppl 2:N81-86
27. Goodman WG, Quarles LD. Development and progression of secondary hyperparathyroidism in chronic kidney disease: Lessons from molecular genetics. Kidney Int 2007
28. Brown AJ, Dusso A, Slatopolsky E. Vitamin D. Am J Physiol 1999; 277:F157-175
29. Quarles LD. Endocrine functions ofbone in mineral metabolism regulation. J Clin Invest 2008;118:3820-3828
30. Saito H, Maeda A, Ohtomo S et al. Circulating FGF-23 is regulated by 1alpha,25-dihydroxyvitamin D3 and phosphorus in vivo. J Biol Chem 2005; 280:2543-2549
31. Shimada T, Hasegawa H, Yamazaki Y et al. FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res 2004; 19:429-435
32. SaitoH,KusanoK,KinosakiMetal.Humanfibroblastgrowthfactor-23 mutants suppressNa+-dependentphosphate cotransport activity and 1alpha,25- dihydroxyvitamin D3 production. J Biol Chem 2003; 278:2206-2211
33. Shimada T, Kakitani M, Yamazaki Y et al. Targeted ablation ofFgf23 demonstrates an essential physiological role ofFGF23 in phosphate and vitamin D metabolism. J Clin Invest 2004; 113:561-568
34. Ben-Dov IZ, Galitzer H, Lavi-Moshayoff V et al. The parathyroid is a target organ for FGF23 in rats. J Clin Invest 2007; 117:4003-4008
35. Ferrari SL, Bonjour JP, Rizzoli R. Fibroblast growth factor-23 relationship to dietary phosphate and renal phosphate handling in healthy young men. J Clin Endocrinol Metab 2005; 90:1519-1524
36. Antoniucci DM, Yamashita T, Portale AA. Dietary phosphorus regulates serum fibroblast growth factor-23 concentrations in healthy men. J Clin Endocrinol Metab 2006; 91:3144-3149
37. Burnett SM, Gunawardene SC, Bringhurst FR et al. Regulation of C-terminal and intact FGF-23 by dietary phosphate in men and women. J Bone Miner Res 2006; 21:1187-1196
38. Jonsson KB, Zahradnik R, Larsson T et al. Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia. N Engl J Med 2003; 348:1656-1663
39. White KE, Jonsson KB, Carn G et al. The autosomal dominant hypophosphatemic rickets (ADHR) gene is a secreted polypeptide overexpressed by tumors that cause phosphate wasting. J Clin Endocrinol Metab 2001; 86:497-500
40. Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23. Nat Genet 2000; 26:345-348
41. Shimada T, Mizutani S, Muto T et al. Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc Natl Acad Sci USA 2001; 98:6500-6505
42. De Beur SM, Finnegan RB, Vassiliadis J et al. Tumors associated with oncogenic osteomalacia express genes important in bone and mineral metabolism. J Bone Miner Res 2002; 17:1102-1110
43. Benet-Pages A, Orlik P, Strom TM et al. An FGF23 missense mutation causes familial tumoral calcinosis with hyperphosphatemia. Hum Mol Genet 2005; 14:385-390
44. Stubbs JR, Liu S, Tang W et al. Role of hyperphosphatemia and 1,25-dihydroxyvitamin D in vascular calcification and mortality in fibroblastic growth factor 23 null mice. J Am Soc Nephrol 2007; 18:2116-2124
45. Slatopolsky E, Delmez JA. Pathogenesis of secondary hyperparathyroidism. Nephrol Dial Transplant 1996; 11 Suppl 3:130-135
46. Slatopolsky E, Finch J, Denda M et al. Phosphorus restriction prevents parathyroid gland growth. High phosphorus directly stimulates PTH secretion in vitro. J Clin Invest 1996; 97:2534-2540
47. Portale AA, Halloran BP, Morris RC, Jr. Physiologic regulation of the serum concentration of 1,25-dihydroxyvitamin D by phosphorus in normal men. J Clin Invest 1989; 83:1494-1499
48. Portale AA, Halloran BP, Murphy MM et al. Oral intake ofphosphorus can determine the serum concentration of 1,25-dihydroxyvitamin D by determining its production rate in humans. J Clin Invest 1986; 77:7-12
49. Llach F, Massry SG. On the mechanism of secondary hyperparathyroidism in moderate renal insufficiency. J Clin Endocrinol Metab 1985; 61:601-606
50. Brown AJ, Zhong M, Ritter C et al. Loss of calcium responsiveness in cultured bovine parathyroid cells is associated with decreased calcium receptor expression. Biochem Biophys Res Commun 1995; 212:861-867
51. Fukuda N, Tanaka H, Tominaga Y et al. Decreased 1,25-dihydroxyvitamin D3 receptor density is associated with a more severe form of parathyroid hyperplasia in chronic uremic patients. J Clin Invest 1993; 92:1436-1443
52. Mitlak BH, Alpert M, Lo C et al. Parathyroid function in normocalcemic renal transplant recipients: evaluation by calcium infusion. J Clin Endocrinol Metab 1991; 72:350-355
53. Fukagawa M. Cell biology of parathyroid hyperplasia in uremia. Am J Med Sci 1999; 317:377-382
54. Rodriguez M, Nemeth E, Martin D. The calcium-sensing receptor: a key factor in the pathogenesis of secondary hyperparathyroidism. Am J Physiol Renal Physiol 2005; 288:F253-264
55. LaClair RE, Hellman RN, Karp SL et al. Prevalence of calcidiol deficiency in CKD: a cross-sectional study across latitudes in the United States. Am J Kidney Dis 2005; 45:1026-1033
56. Levin A, Bakris GL, Molitch M et al. Prevalence of abnormal serum vitamin D, PTH, calcium and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. Kidney Int 2007; 71:31-38
57. Young EW, Akiba T, Albert JM et al. Magnitude and impact of abnormal mineral metabolism in hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 2004; 44:34-38
58. Gutierrez OM, Isakova T, Andress DL et al. Prevalence and severity of disordered mineral metabolism in Blacks with chronic kidney disease. Kidney Int 2008; 73:956-962
59. Gutierrez O, Isakova T, Rhee E et al. Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease. J Am Soc Nephrol 2005; 16:2205-2215
60. Gonzalez EA, Sachdeva A, Oliver DA et al. Vitamin D insufficiency and deficiency in chronic kidney disease. A single center observational study. Am J Nephrol 2004; 24:503-510
61. Larsson T, Nisbeth U, Ljunggren O et al. Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers. Kidney Int 2003; 64:2272-2279
62. Shigematsu T, Kazama JJ, Yamashita T et al. Possible involvement of circulating fibroblast growth factor 23 in the development of secondary hyperparathyroidism associated with renal insufficiency. Am J Kidney Dis 2004; 44:250-256
63. KomabaH, Fukagawa M. FGF23-parathyroidinteraction: implications in chronickidney disease. Kidney Int2009
64. Denda M, Finch J, Slatopolsky E. Phosphorus accelerates the development of parathyroid hyperplasia and secondary hyperparathyroidism in rats with renal failure. Am J Kidney Dis 1996; 28:596-602
65. Lopez-Hilker S, Dusso AS, Rapp NS et al. Phosphorus restriction reverses hyperparathyroidism in uremia independent of changes in calcium and calcitriol. Am J Physiol 1990; 259:F432-437
66. Kusano K, Segawa H, Ohnishi R et al. Role oflow protein and low phosphorus diet in the progression of chronic kidney disease in uremic rats. J Nutr Sci Vitaminol (Tokyo) 2008; 54:237-243
67. Barsotti G, Giannoni A, Morelli E et al. The decline of renal function slowed by very low phosphorus intake in chronic renal patients following a low nitrogen diet. Clin Nephrol 1984; 21:54-59
68. Koizumi T, Murakami K, Nakayama H et al. Role of dietary phosphorus in the progression of renal failure. Biochem Biophys Res Commun 2002; 295:917-921
69. Martinez I, Saracho R, Montenegro J et al. The importance of dietary calcium and phosphorous in the secondary hyperparathyroidism of patients with early renal failure. Am J Kidney Dis 1997; 29:496-502
70. Portale AA, Booth BE, Halloran BP et al. Effect of dietary phosphorus on circulating concentrations of 1.25-dihydroxyvitamin D and immunoreactive parathyroid hormone in children with moderate renal insufficiency. J Clin Invest 1984; 73:1580-1589
71. Hasegawa H, Iijima K, Shimada T et al. FGF-23 plays a critical role in the development of reduced serum 1.25-dihydroxyvitamin D levels associated with renal insufficiency (Abstract). J Am Soc Nephrol2003; 14:40A
72. Yamashita T. Involvement of FGF-23 in abnormal vitamin D and mineral metabolism associated with renal insufficiency (Abstract). J Am Soc Nephrol 2002; 13:577A
73. Koiwa F, Kazama JJ, Tokumoto A et al. Sevelamer hydrochloride and calcium bicarbonate reduce serum fibroblast growth factor 23 levels in dialysis patients. Ther Apher Dial 2005; 9:336-339
74. Oliveira RB, Cancela ALE, Graciolli FG et al. Early control of PTH and FGF23 in normophosphatemic CKD patients: a new target in CKD-MBD therapy? CJASN 2009;In Press
75. Nagano N, Miyata S, Abe M et al. Effect of manipulating serum phosphorus with phosphate binder on circulating PTH and FGF23 in renal failure rats. Kidney Int2006;69:531-537
76. McClellan W, Warnock DG, McClure L et al. Racial differences in the prevalence of chronic kidney disease among participants in the Reasons for Geographic and Racial Differences in Stroke (REGARDS) Cohort Study. J Am Soc Nephrol 2006; 17:1710-1715
77. Xue JL, Eggers PW, Agodoa LY et al. Longitudinal study of racial and ethnic differences in developing end-stage renal disease among aged medicare beneficiaries. J Am Soc Nephrol 2007; 18:1299-1306
78. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003; 42:S1-201
79. CKD-MBD Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl 2009:S1-130
80. Blacher J, Asmar R, Djane S et al. Aortic pulse wave velocity as a marker of cardiovascular risk in hypertensive patients. Hypertension 1999; 33:1111-1117
81. Klassen PS, Lowrie EG, Reddan DN et al. Association between pulse pressure and mortality in patients undergoing maintenance hemodialysis. JAMA 2002; 287:1548-1555
82. Cozzolino M, Brancaccio D, Gallieni M et al. Pathogenesis of vascular calcification in chronic kidney disease. Kidney Int 2005; 68:429-436
83. Blacher J, Guerin AP, Pannier B et al. Arterial calcifications, arterial stiffness and cardiovascular risk in end-stage renal disease. Hypertension 2001; 38:938-942
84. Goodman WG, Goldin J, Kuizon BD et al. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 2000; 342:1478-1483
85. Moe SM, ONeill KD, Reslerova M et al. Natural history of vascular calcification in dialysis and transplant patients. Nephrol Dial Transplant 2004; 19:2387-2393
86. Adeney KL, Siscovick DS, Ix JH et al. Association of serum phosphate with vascular and valvular calcification in moderate CKD. J Am Soc Nephrol 2009; 20:381-387
87. Jono S, McKee MD, Murry CE et al. Phosphate regulation of vascular smooth muscle cell calcification. Circ Res 2000; 87:E10-17
88. Achinger SG, Ayus JC. Left ventricular hypertrophy: is hyperphosphatemia among dialysis patients a risk factor? J Am Soc Nephrol 2006; 17:S255-261
89. Ayus JC, Mizani MR, Achinger SG et al. Effects of short daily versus conventional hemodialysis on left ventricular hypertrophy and inflammatory markers: a prospective, controlled study. J Am Soc Nephrol 2005; 16:2778-2788
90. Culleton BF, Walsh M, Klarenbach SW et al. Effect of frequent nocturnal hemodialysis vs conventional hemodialysis on left ventricular mass and quality of life: a randomized controlled trial. JAMA 2007; 298:1291-1299
91. Young EW, Albert JM, Satayathum S et al. Predictors and consequences of altered mineral metabolism: the Dialysis Outcomes and Practice Patterns Study. Kidney Int 2005; 67:1179-1187
92. Kalantar-Zadeh K, Kuwae N, Regidor DL et al. Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients. Kidney Int 2006; 70:771-780
93. Menon V, Greene T, Pereira AA et al. Relationship of phosphorus and calcium-phosphorus product with mortality in CKD. Am J Kidney Dis 2005; 46:455-463
94. Isakova T, Gutierrez O, Shah A et al. Postprandial mineral metabolism and secondary hyperparathyroidism in early CKD. J Am Soc Nephrol 2008; 19:615-623
95. MarkowitzM,RotkinL, RosenJF.Circadianrhythmsofbloodminerals inhumans. Science 1981;213:672-674
96. Haut LL, Alfrey AC, Guggenheim S et al. Renal toxicity of phosphate in rats. Kidney Int 1980; 17:722-731
97. Fliser D, Kollerits B, NeyerU et al. Fibroblast growth factor 23 (FGF23) predicts progression of chronic kidney disease: the Mild to Moderate Kidney Disease (MMKD) Study. J Am Soc Nephrol 2007; 18:2600-2608
98. Gutierrez OM, Januzzi JL, Isakova T et al. Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease. Circulation 2009; 119:2545-2552
99. Mirza MA, Larsson A, Melhus H et al. Serum intact FGF23 associate with left ventricular mass, hypertrophy and geometry in an elderly population. Atherosclerosis 2009; 207:546-551
100. Mirza MA, Larsson A, Lind L et al. Circulating fibroblast growth factor-23 is associated with vascular dysfunction in the community. Atherosclerosis 2009; 205:385-390
101. HsuHJ, Wu MS. Fibroblast growth factor 23: a possible cause ofleft ventricular hypertrophy in hemodialysis patients. Am J Med Sci 2009; 337:116-122
102. Jean G, Terrat JC, Vanel T et al. High levels of serum fibroblast growth factor (FGF)-23 are associated with increased mortality in long haemodialysis patients. Nephrol Dial Transplant 2009; 24:2792-2796
103. Kojima F, Uchida K, Ogawa T et al. Plasma levels of fibroblast growth factor-23 and mineral metabolism in diabetic and nondiabetic patients on chronic hemodialysis. Int Urol Nephrol 2008; 40:1067-1074
104. Gutierrez OM, Mannstadt M, Isakova T et al. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med 2008; 359:584-592
105. Shimada T, Urakawa I, Isakova T et al. Circulating Fibroblast Growth Factor 23 in Patients with End-Stage Renal Disease Treated by Peritoneal Dialysis Is Intact and Biologically Active. J Clin Endocrinol Metab 2009
106. Isakova T, Gutierrez OM, Chang Y et al. Phosphorus binders and survival on hemodialysis. J Am Soc Nephrol 2009; 20:388-396
107. Nishi H, Nii-Kono T, Nakanishi S et al. Intravenous calcitriol therapy increases serum concentrations of fibroblast growth factor-23 in dialysis patients with secondary hyperparathyroidism. Nephron Clin Pract 2005; 101:c94-99
108. Wetmore JB, Liu S, Krebill R et al. Effects of cinacalcet and concurrent low-dose vitamin D on FGF23 levels in ESRD. Clin J Am Soc Nephrol 2010;5(1):110-6